Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Identification of HER2+ malignant cells in gastric tumors from single-cell RNAseq data.
Authors
Zhiming Zhang
Shanghai OE Biotech Co., Ltd, Shanghai, China;
Zhiming Zhang , Xiufeng Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 417)
DOI
10.1200/JCO.2023.41.4_suppl.417
Abstract #
417
Poster Bd #
H20
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).
First Author: Erica Michelle Stringer-Reasor
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The expanded indications of HER2-targeted therapies by monitoring of circulating tumor cells.
First Author: Yasuaki Kimura
Poster
2023 ASCO Annual Meeting
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
First Author: Seunghwan Shin
Poster
2023 ASCO Annual Meeting
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
First Author: Joshua Z. Drago